Literature DB >> 25524170

Solution studies on DNA interactions of substitution-inert platinum complexes mediated via the phosphate clamp.

Y Qu1, R G Kipping, N P Farrell.   

Abstract

The phosphate clamp is a distinct mode of ligand-DNA binding where the molecular recognition is manifested through ("non-covalent") hydrogen-bonding from am(m)ines of polynuclear platinum complexes to the phosphate oxygens on the oligonucleotide backbone. This third mode of DNA binding is unique to the "classical" DNA intercalators and minor groove binding agents and even the closely related covalently binding mononuclear and polynuclear drugs. 2D (1)H NMR studies on the Dickerson-Drew dodecamer (DDD, d(CGCGAATTCGCG)2) showed significant A-T contacts mainly on nucleotides A6, T7 and T8 implying a selective bridging from C9G10 in the 3' direction to C9G10 of the opposite strand. {(1)H, (15)N} HSQC NMR spectroscopy using the fully (15)N-labelled compound [{trans-Pt(NH2)3(H2N(CH2)6NH3}2μ-(H2N(CH2)6NH2)2(Pt(NH3)2](8+) (TriplatinNC) showed at pH 6 significant chemical shifts and (1)J((195)Pt-(15)N) coupling constants for the free drug and DDD-TriplatinNC at pH 7 indicative of formation of the phosphate clamp. (31)P NMR results are also reported for the hexamer d(CGTACG)2 showing changes in (31)P NMR chemical shifts indicative of changes around the phosphorus center. The studies confirm the DNA binding modes by substitution-inert (non-covalent) polynuclear platinum complexes and help in further establishing the chemotype as a new class of potential anti-tumour agents in their own right with a distinct profile of biological activity.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25524170      PMCID: PMC4323935          DOI: 10.1039/c4dt03237c

Source DB:  PubMed          Journal:  Dalton Trans        ISSN: 1477-9226            Impact factor:   4.390


  27 in total

1.  Substitution-inert trinuclear platinum complexes efficiently condense/aggregate nucleic acids and inhibit enzymatic activity.

Authors:  Jaroslav Malina; Nicholas P Farrell; Viktor Brabec
Journal:  Angew Chem Int Ed Engl       Date:  2014-09-24       Impact factor: 15.336

2.  DNA condensing effects and sequence selectivity of DNA binding of antitumor noncovalent polynuclear platinum complexes.

Authors:  Jaroslav Malina; Nicholas P Farrell; Viktor Brabec
Journal:  Inorg Chem       Date:  2014-01-16       Impact factor: 5.165

3.  DNA interstrand cross-links of an antitumor trinuclear platinum(II) complex: thermodynamic analysis and chemical probing.

Authors:  Jaroslav Malina; Nicholas P Farrell; Viktor Brabec
Journal:  Chem Asian J       Date:  2011-03-29

4.  Effects of noncovalent platinum drug-protein interactions on drug efficacy: use of fluorescent conjugates as probes for drug metabolism.

Authors:  Brad T Benedetti; Erica J Peterson; Peyman Kabolizadeh; Alberto Martínez; Ralph Kipping; Nicholas P Farrell
Journal:  Mol Pharm       Date:  2011-05-16       Impact factor: 4.939

5.  NanoSIMS multi-element imaging reveals internalisation and nucleolar targeting for a highly-charged polynuclear platinum compound.

Authors:  Louise E Wedlock; Matt R Kilburn; Rong Liu; Jeremy A Shaw; Susan J Berners-Price; Nicholas P Farrell
Journal:  Chem Commun (Camb)       Date:  2013-08-11       Impact factor: 6.222

6.  A role for water molecules in DNA-ligand minor groove recognition.

Authors:  Binh Nguyen; Stephen Neidle; W David Wilson
Journal:  Acc Chem Res       Date:  2009-01-20       Impact factor: 22.384

Review 7.  DNA minor groove binders: back in the groove.

Authors:  Xuemei Cai; Phillip J Gray; Daniel D Von Hoff
Journal:  Cancer Treat Rev       Date:  2009-03-27       Impact factor: 12.111

Review 8.  Structure-based DNA-targeting strategies with small molecule ligands for drug discovery.

Authors:  Jia Sheng; Jianhua Gan; Zhen Huang
Journal:  Med Res Rev       Date:  2013-04-30       Impact factor: 12.944

9.  The phosphate clamp: sequence selective nucleic acid binding profiles and conformational induction of endonuclease inhibition by cationic Triplatin complexes.

Authors:  Andreea Prisecaru; Zara Molphy; Ralph G Kipping; Erica J Peterson; Yun Qu; Andrew Kellett; Nicholas P Farrell
Journal:  Nucleic Acids Res       Date:  2014-11-20       Impact factor: 16.971

10.  Nucleolar targeting by platinum: p53-independent apoptosis follows rRNA inhibition, cell-cycle arrest, and DNA compaction.

Authors:  Erica J Peterson; Vijay R Menon; Laura Gatti; Ralph Kipping; Dilhara Dewasinghe; Paola Perego; Lawrence F Povirk; Nicholas P Farrell
Journal:  Mol Pharm       Date:  2014-12-03       Impact factor: 4.939

View more
  4 in total

1.  Novel enantiopure cyclopentadienyl Ti(IV) oximato compounds as potential anticancer agents.

Authors:  Isabel de la Cueva-Alique; Laura Muñoz-Moreno; Yosra Benabdelouahab; Benelita T Elie; Mohammed Amin El Amrani; Marta E G Mosquera; María Contel; Ana M Bajo; Tomás Cuenca; Eva Royo
Journal:  J Inorg Biochem       Date:  2015-12-09       Impact factor: 4.155

2.  Exploitation of Sulfated Glycosaminoglycan Status for Precision Medicine of Triplatin in Triple-Negative Breast Cancer.

Authors:  James D Hampton; Erica J Peterson; Nicholas P Farrell; Jennifer E Koblinski; Samantha J Katner; Tia H Turner; Mohammad A Alzubi; J Chuck Harrell; Mikhail G Dozmorov; Joseph B McGee Turner; Pam J Gigliotti; Vita Kraskauskiene; Mayuri Shende; Michael O Idowu; Madhavi Puchalapalli; Bin Hu; Larisa Litovchick; Eriko Katsuta; Kazuaki Takabe
Journal:  Mol Cancer Ther       Date:  2021-11-23       Impact factor: 6.009

3.  Antiangiogenic platinum through glycan targeting.

Authors:  Erica J Peterson; A Gerard Daniel; Samantha J Katner; Lisa Bohlmann; Chih-Wei Chang; Anna Bezos; Christopher R Parish; Mark von Itzstein; Susan J Berners-Price; Nicholas P Farrell
Journal:  Chem Sci       Date:  2016-08-12       Impact factor: 9.825

Review 4.  Molecular methods for assessment of non-covalent metallodrug-DNA interactions.

Authors:  Andrew Kellett; Zara Molphy; Creina Slator; Vickie McKee; Nicholas P Farrell
Journal:  Chem Soc Rev       Date:  2019-02-18       Impact factor: 54.564

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.